| Literature DB >> 34960000 |
Gemma Caterina Maria Rossi1, Luigia Scudeller2, Federica Bettio1, Giovanni Milano1.
Abstract
The aims of the study were to investigate the ability and effectiveness of an oral intake of a fixed combination of zinc, L-carnitine, elderberry extract, black currant and Eleutherococcus extract in controlling the symptoms of eyestrain in videoterminal (VDT) users and to record its effects on contrast sensitivity. A single-center, phase II, observational, case-control, 1-month study in VDT workers without dry eye disease was carried out. Demographics and number of actual hours at VDT/day were taken into account. All subjects underwent a complete ophthalmic examination, including assessment of contrast sensitivity, and completed the computer vision symptom scale questionnaire at baseline and one month later. A total of 30 Caucasian subjects adhered to the required inclusion criteria and completed the study; 15 subjects were treated (T) and 15 were controls (C). All clinical data at baseline were similar in both groups (p > 0.05): after one month, all subjects had stable visual acuity, refractive defect and intraocular pressure (IOP); screen exposure time was unchanged. Regarding symptoms, at randomization, the groups had a similar score: 33.1 ± 3.3 in T and 32.8 ± 5.6 in C. One month later, the computer vision symptom scale (CVSS) questionnaire score decreased by -14.1 ± 3, 1 (p = 0.000) and -2.3 ± 1.8 (p = 0.568), respectively. Regarding contrast sensitivity, in group C the values of spatial frequencies remained unchanged, while they improved in almost all the cycles per degree stimuli in the treated group. Oral intake of a fixed combination of zinc, L-carnitine, elderberry extract, black currant and eleutherococcus extract can significantly improve contrast sensitivity and symptoms in VDT workers with no signs of dry eye disease.Entities:
Keywords: COVID-19; VDT; contrast sensitivity; diet; dry eye; eye; lifestyle; nutraceutics; ocular surface; quality of life; video display terminal
Mesh:
Substances:
Year: 2021 PMID: 34960000 PMCID: PMC8705792 DOI: 10.3390/nu13124449
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Demographics at baseline.
| Treated (T) | Control (C) | |
|---|---|---|
| Age (years, mean ± SD) | 44.3 ± 9.5 | 45.6 ± 8.7 |
| Gender (women, | 11 (77.3) | 12 (80) |
| Schooling level ( | ||
| - secondary school | 4 (26.7) | 6 (40) |
| - high school | 8 (53.3) | 6 (40) |
| - bachelor | 3 (20) | 3 (20) |
| Daily time spent at VDT (hour.minute) | 7.30 ± 15 | 7.15 ± 30 |
| Systemic diseases | ||
| - systemic hypertension | 3 (20) | 2 (13.3) |
| - thyroid disorders | 1 (6.6) | 1 (6.6) |
| - venous disorder | - | 1 (6.6) |
| - anxiety | 1 (6.6) | - |
SD: Standard deviation.
Figure 1CVSS17 questionnaire score in treated group and in control at enrollment and 1 month later. The score significantly improved from t0 to t1 in treated.
Contrast sensitivity changes over one month period in subjects receiving a tablet a day of Meramirt CM (treated, T) and in a control group (control, C). (+ = improved examination; − = worsened examination).
| Spatial Frequency | Normal Values (Range) | Contrast Sensitivity | Contrast Sensitivity Variation |
|
|---|---|---|---|---|
| Treated (T) | ||||
| 1.5 | 30–120 | 52.3 ± 16.6 | +37.7 ± 15.1 | 0.012 |
| 3 | 40–170 | 78.3 ± 25.2 | +27.7 ± 15.1 | 0.052 |
| 6 | 50–180 | 46.5 ± 9.9 | +6 ± 8.5 | n.s. |
| 12 | 20–130 | 18.7 ± 2.6 | +16.5 ± 2.5 | 0.010 |
| 18 | 5–70 | 12.2 ± 1.8 | +15 ± 1.7 | 0.000 |
| Control (C) | ||||
| 1.5 | 30–120 | 65.4 ± 17.6 | −2.37 ± 16.5 | n.s. |
| 3 | 40–170 | 101.2 ± 36.6 | +8.1 ± 9.2 | n.s. |
| 6 | 50–180 | 69.8 ± 9.5 | −4.7 ± 4.5 | n.s. |
| 12 | 20–130 | 29.5 ± 6.5 | −1.5 ± 7.2 | n.s. |
| 18 | 5–70 | 12.5 ± 2.3 | +4.1 ± 2.8 | n.s. |